Modulation of MDR1 and CYP3A Expression by Dexamethasone: Evidence for an Inverse Regulation in Adrenals
- 18 November 1998
- journal article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 252 (2), 392-395
- https://doi.org/10.1006/bbrc.1998.9662
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic InteractionsClinical Pharmacokinetics, 1997
- Molecular Mechanisms of Multidrug Resistance in Cancer ChemotherapyPathology - Research and Practice, 1996
- P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclaturePharmacogenetics, 1996
- Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapyMolecular Carcinogenesis, 1995
- Modulation of multidrug resistance gene expression by dexamethasone in cultured hepatoma cells.Endocrinology, 1993
- Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities.Molecular and Cellular Biology, 1990
- Structure and expression of the human MDR (P-glycoprotein) gene family.Molecular and Cellular Biology, 1989
- The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues.Molecular and Cellular Biology, 1989
- Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine.Proceedings of the National Academy of Sciences of the United States of America, 1987
- Isolation and expression of a complementary DNA that confers multidrug resistanceNature, 1986